Molecular and clinical characterization of plasmid-mediated AmpC β-lactamase-producing Escherichia coli bacteraemia: A comparison with extended-spectrum β-lactamase-producing and non-resistant E. coli bacteraemia

Clinical Microbiology and Infection

Volumn 19, Issue 2, 2013, Pages 161-168

  Matsumura, Y ^a   Nagao, M ^a   Iguchi, M ^b   Yagi, T ^b   Komori, T ^c   Fujita, N ^c   Yamamoto, M ^a   Matsushima, A ^a   Takakura, S ^a   Ichiyama, S ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

AmpC lactamase; Bloodstream infection; Escherichia coli; Extended spectrum lactamase; Molecular epidemiology; Sequence type

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; EXTENDED SPECTRUM BETA LACTAMASE;

AMPC BETA LACTAMASE PRODUCING ESCHERICHIA COLI; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; CONTROLLED STUDY; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; HUMAN; INTRAVASCULAR CATHETER; MAJOR CLINICAL STUDY; MALE; NON RESISTANT ESCHERICHIA COLI; NONHUMAN; PHYLOGENY; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SEROTYPE;

ESCHERICHIA COLI;

EID: 84873524137     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03762.x     Document Type: Article

References (30)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.
2. Rossolini GM, D'Andrea MM, Mugnaioli C. The spread of CTX-M-type extended-spectrum beta-lactamases. Clin Microbiol Infect 2008; 14 (suppl 1): 33-41.
3. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011; 66: 1-14.
4. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev 2009; 22: 161-182.
5. Falagas ME, Karageorgopoulos DE. Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect 2009; 73: 345-354.
6. Doi Y, Paterson DL. Detection of plasmid-mediated class C beta-lactamases. Int J Infect Dis 2007; 11: 191-197.
7. Friedman N, Kaye K, Stout J et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137: 791-797.
8. Bone RC, Balk RA, Cerra FB et al American College of Chest Physicians/Society of Critical Care Medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. CLSI document M100-S20. Wayne, PA: CLSI, 2010.
10. Dallenne C, Da Costa A, Decré D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in enterobacteriaceae. J Antimicrob Chemother 2010; 65: 490-495.
11. Saladin M, Cao VT, Lambert T et al. Diversity of CTX-M beta-lactamases and their promoter regions from enterobacteriaceae isolated in three Parisian hospitals. FEMS Microbiol Lett 2002; 209: 161-168.
12. Pérez-Pérez F, Hanson N. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002; 40: 2153-2162.
13. Yagi T, Kurokawa H, Shibata N, Shibayama K, Arakawa Y. A preliminary survey of extended-spectrum beta-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan. FEMS Microbiol Lett 2000; 184: 53-56.
14. Briñas L, Zarazaga M, Sáenz Y, Ruiz-Larrea F, Torres C. Beta-lactamases in ampicillin-resistant Escherichia coli isolates from foods, humans, and healthy animals. Antimicrob Agents Chemother 2002; 46: 3156-3163.
15. Kim HB, Park CH, Kim CJ, Kim EC, Jacoby GA, Hooper DC. Prevalence of plasmid-mediated quinolone resistance determinants over a 9-year period. Antimicrob Agents Chemother 2009; 53: 639-645.
16. Gordon DM, Clermont O, Tolley H, Denamur E. Assigning Escherichia coli strains to phylogenetic groups: multi-locus sequence typing versus the PCR triplex method. Environ Microbiol 2008; 10: 2484-2496.
17. Clermont O, Lavollay M, Vimont S et al. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J Antimicrob Chemother 2008; 61: 1024-1028.
18. Wiedmann-al-Ahmad M, Tichy H, Schön G. Characterization of Acinetobacter type strains and isolates obtained from wastewater treatment plants by PCR fingerprinting. Appl Environ Microbiol 1994; 60: 4066-4071.
19. Suzuki S, Shibata N, Yamane K, Wachino J, Ito K, Arakawa Y. Change in the prevalence of extended-spectrum-beta-lactamase-producing Escherichia coli in Japan by clonal spread. J Antimicrob Chemother 2009; 63: 72-79.
20. Pitout JD, Gregson DB, Campbell L, Laupland KB. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary health region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob Agents Chemother 2009; 53: 2846-2851.
21. Coque TM, Novais A, Carattoli A et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerg Infect Dis 2008; 14: 195-200.
22. Blanco J, Mora A, Mamani R et al. National survey of Escherichia coli causing extraintestinal infections reveals the spread of drug-resistant clonal groups O25b:H4-B2-ST131, O15:H1-D-ST393 and CgA-D-ST69 with high virulence gene content in Spain. J Antimicrob Chemother 2011; 66: 2011-2021.
23. Oteo J, Diestra K, Juan C et al. Extended-spectrum beta-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/a, ST23 complex/a and ST131/B2. Int J Antimicrob Agents 2009; 34: 173-176.
24. Yamasaki K, Komatsu M, Abe N et al. Laboratory surveillance for prospective plasmid-mediated AmpC beta-lactamases in the Kinki region of Japan. J Clin Microbiol 2010; 48: 3267-3273.
25. Corvec S, Crémet L, Leprince C et al. Epidemiology of Escherichia coli clinical isolates producing AmpC plasmidic beta-lactamase during a 5-year period in a French teaching hospital. Diagn Microbiol Infect Dis 2010; 67: 277-281.
26. Jørgensen RL, Nielsen JB, Friis-Møller A, Fjeldsøe-Nielsen H, Schønning K. Prevalence and molecular characterization of clinical isolates of Escherichia coli expressing an AmpC phenotype. J Antimicrob Chemother 2010; 65: 460-464.
27. Naseer U, Haldorsen B, Simonsen GS, Sundsfjord A. Sporadic occurrence of CMY-2-producing multidrug-resistant Escherichia coli of ST-complexes 38 and 448, and ST131 in Norway. Clin Microbiol Infect 2010; 16: 171-178.
28. Oteo J, Cercenado E, Cuevas O et al. AmpC beta-lactamases in Escherichia coli: emergence of CMY-2-producing virulent phylogroup D isolates belonging mainly to STs 57, 115, 354, 393, and 420, and phylogroup B2 isolates belonging to the international clone O25b-ST131. Diagn Microbiol Infect Dis 2010; 67: 270-276.
29. Yan JJ, Ko WC, Wu JJ, Tsai SH, Chuang CL. Epidemiological investigation of bloodstream infections by extended spectrum cephalosporin-resistant Escherichia coli in a Taiwanese teaching hospital. J Clin Microbiol 2004; 42: 3329-3332.
30. Courpon-Claudinon A, Lefort A, Panhard X et al. Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features. Clin Microbiol Infect 2011; 17: 557-565.